Uniphar Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.20 M
as on 09-12-2024
- Paid Up Capital ₹ 0.75 M
as on 09-12-2024
- Company Age 11 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 0.50 M
as on 09-12-2024
- Revenue 26.97%
(FY 2022)
- Profit 122.85%
(FY 2022)
- Ebitda -4.54%
(FY 2022)
- Net Worth 33.25%
(FY 2022)
- Total Assets 13.29%
(FY 2022)
About Uniphar Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.20 M and a paid-up capital of Rs 0.75 M.
The company has closed loans amounting to ₹0.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Rajeev Matta, Kamna Matta, Adesh Saini, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232CH2013PTC034725
- Company No.
034725
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Sep 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Uniphar Biotech Private Limited offer?
Uniphar Biotech Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Pharmaceutical Medicine, Pharma & Bioanalytical Services, Pharmaceutical Third Party Manufacturing, Antihistamines, Sexual Wellness Products, Fertility Enhancer.
Who are the key members and board of directors at Uniphar Biotech?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajeev Matta  | Director | 13-Sep-2013 | Current |
| Kamna Matta | Director | 13-Sep-2013 | Current |
| Adesh Saini | Director | 13-Sep-2013 | Current |
| Ashwani Tejpal | Director | 12-Apr-2017 | Current |
Financial Performance of Uniphar Biotech.
Uniphar Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 26.97% increase. The company also saw a substantial improvement in profitability, with a 122.85% increase in profit. The company's net worth Soared by an impressive increase of 33.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Uniphar Biotech?
Unlock access to Uniphar Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Abiz Pharma Private LimitedActive 6 years 10 monthsRajeev Matta, Kamna Matta and 2 more are mutual person
Alester Pharma Private LimitedActive 9 years 25 daysRajeev Matta, Kamna Matta and 1 more are mutual person
Arovea Lifesciences Private LimitedActive 6 years 2 monthsRajeev Matta and Adesh Saini are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 04 Apr 2022 | ₹0.50 M | Satisfied |
How Many Employees Work at Uniphar Biotech?
Unlock and access historical data on people associated with Uniphar Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Uniphar Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Uniphar Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
